Johnson & Johnson (NYSE:JNJ) was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday. They currently have a $123.13 price target on the stock. Vetr‘s target price suggests a potential upside of 3.55% from the stock’s current price.

A number of other analysts have also weighed in on JNJ. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Friday, June 3rd. Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. BMO Capital Markets reiterated an “outperform” rating and set a $132.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 20th. Finally, Jefferies Group lowered their price objective on shares of Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 13th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $119.53.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.81% during mid-day trading on Wednesday, reaching $118.91. The company’s stock had a trading volume of 6,337,292 shares. Johnson & Johnson has a 12 month low of $89.90 and a 12 month high of $126.07. The company has a market cap of $325.32 billion, a P/E ratio of 22.16 and a beta of 0.61. The company has a 50-day moving average of $120.26 and a 200-day moving average of $116.14.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/johnson-johnson-jnj-rating-lowered-to-hold-at-vetr-inc.html

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.06. The company earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Equities research analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 2.69%. The ex-dividend date was Friday, August 19th. Johnson & Johnson’s dividend payout ratio is presently 60.15%.

In other news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at approximately $3,582,786.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Choate Investment Advisors boosted its position in shares of Johnson & Johnson by 10.6% in the fourth quarter. Choate Investment Advisors now owns 78,607 shares of the company’s stock valued at $8,220,000 after buying an additional 7,523 shares in the last quarter. Founders Capital Management LLC boosted its position in Johnson & Johnson by 2.0% in the first quarter. Founders Capital Management LLC now owns 57,005 shares of the company’s stock worth $6,168,000 after buying an additional 1,111 shares during the period. First American Trust FSB boosted its position in Johnson & Johnson by 1,942.4% in the first quarter. First American Trust FSB now owns 50,427 shares of the company’s stock worth $5,456,000 after buying an additional 47,958 shares during the period. Stock Yards Bank & Trust Co. boosted its position in Johnson & Johnson by 3.3% in the first quarter. Stock Yards Bank & Trust Co. now owns 81,147 shares of the company’s stock worth $8,780,000 after buying an additional 2,555 shares during the period. Finally, Indiana Trust & Investment Management CO boosted its position in Johnson & Johnson by 3.1% in the first quarter. Indiana Trust & Investment Management CO now owns 13,259 shares of the company’s stock worth $1,435,000 after buying an additional 395 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.